You searched for "retina"
Beware the disc in myopic patients
1 August 2018
| Eulee Seow
|
EYE - Glaucoma
Glaucoma is a chronic and progressive optic neuropathy characterised by damage of retinal ganglion cells. Evaluation of structural damage of the optic nerve is important in glaucoma diagnosis. The ISNT rule states that the neuroretinal rim width is generally widest...
Type 3 macular neovascularisation (MNV) due to age-related macular degeneration
3 October 2024
| Sofia Rokerya
|
EYE - Vitreo-Retinal
This paper systematically reviews and summarises the current knowledge on type 3 neovascularisation due to age-related macular degeneration which is defined as neovascularisation originating from the retinal deep capillary plexus that grows towards the outer retina often penetrating the level...
Pathological myopia: a trainer’s perceptive
3 April 2024
| Anitha Priya Arun Shankar, Adelehin Ijasan
|
EYE - Vitreo-Retinal
High myopia is defined as myopic refraction of greater than -6 dioptres with an axial length greater than 26.5mm, while pathological myopia is myopic refraction with posterior pole degeneration [1]. These degenerative changes can affect a young population and in...
My top five: Innovative approaches to dry AMD
2 February 2024
| Nikhil Sharma
|
EYE - Vitreo-Retinal
Age-related macular degeneration (AMD) is one of the leading causes of irreversible blindness in the developing world with its prevalence rising alongside age. In societies characterised by ageing populations, it is imperative we explore more effective treatment to alleviate the...
My Top Five: Innovative approaches to dry AMD
2 February 2024
| Nikhil Sharma
|
EYE - General
Age-related macular degeneration (AMD) is one of the leading causes of irreversible blindness in the developing world with its prevalence rising alongside age. In societies characterised by ageing populations, it is imperative we explore more effective treatment to alleviate the...
Correlation between anti-retinal antibodies and proliferative vitreoretinopathy (PVR)
1 October 2018
| Kurt Spiteri Cornish
|
EYE - Vitreo-Retinal
The pathological basis of PVR is not clearly understood and there are no effective medications targeting this condition. This cross-sectional study looked at the possible association of anti-retinal antibodies with patients with PVR and retinal detachment (RD). Aqueous and vitreous...
Choroidal folds
1 August 2014
| H Ali, Sumith Perera
|
EYE - Cataract, EYE - Cornea, EYE - General, EYE - Glaucoma, EYE - Imaging, EYE - Neuro-ophthalmology, EYE - Oculoplastic, EYE - Oncology, EYE - Orbit, EYE - Paediatrics, EYE - Pathology, EYE - Refractive, EYE - Strabismus, EYE - Vitreo-Retinal
Choroidal folds are undulations of the choroid, Bruch’s membrane and pigment epithelium, with wrinkling of the overlying retina. They may be idiopathic but can also be caused by a number of different conditions. Case report A 60-year-old male patient was...
Sharing best practice and landmark evidence in glaucoma care
Evolving technology, best practice and landmark evidence in glaucoma care were reviewed by an international expert faculty in session presentations and debates during the 11th Moorfields International Glaucoma Symposium 2019. The authors were meeting chairs and provide an overview of...Management of proliferative diabetic retinopathy
1 August 2014
| Felicity Allen, Samantha S Mann
|
EYE - Vitreo-Retinal
Diabetic retinopathy is a major cause of blindness in the working-age population. Due to the worsening global epidemic of diabetes, the incidence of morbidity caused by the disease is set to increase [1]. The prevalence of diabetes in the UK...
The blue-light hazard – is it true?
Simerdip Kaur takes a look at the latest ophthalmology-related news stories and asks which are based on facts and which are ‘fake news’. Headline: The blue-light hazard – is it true? Blue light is part of the visible optical spectrum...Neovascular AMD: fresh recommendations underline standards of best practice
1 December 2013
| Rod McNeil
The management of neovascular age-related macular degeneration (nAMD) has advanced dramatically over the past seven years, with the introduction of targeted new therapies that successfully maintain or improve vision in a majority of affected individuals. It’s a fast moving field,...
